These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 26051268

  • 1. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination.
    Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, Baxter R, Donahue JG, Naleway AL, Jacobsen SJ.
    Mayo Clin Proc; 2015 Jul; 90(7):865-73. PubMed ID: 26051268
    [Abstract] [Full Text] [Related]

  • 2. Risk of Disseminated Varicella Zoster in Immunosuppressed Patients Receiving Zoster Vaccination.
    Bubb MR.
    Mayo Clin Proc; 2015 Nov; 90(11):1585-6. PubMed ID: 26541254
    [No Abstract] [Full Text] [Related]

  • 3. In reply--Risk of Disseminated Varicella Zoster in Immunosuppressed Patients Receiving Zoster Vaccination.
    Cheetham TC, Sy LS, Jacobsen SJ.
    Mayo Clin Proc; 2015 Nov; 90(11):1586-7. PubMed ID: 26541255
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases.
    Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang YX.
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1341-1347. PubMed ID: 30326303
    [Abstract] [Full Text] [Related]

  • 5. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination.
    Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF.
    Pediatr Infect Dis J; 2009 Nov; 28(11):954-9. PubMed ID: 19536039
    [Abstract] [Full Text] [Related]

  • 6. Zoster vaccine: current status and future prospects.
    Oxman MN.
    Clin Infect Dis; 2010 Jul 15; 51(2):197-213. PubMed ID: 20550454
    [Abstract] [Full Text] [Related]

  • 7. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States.
    Patel MS, Gebremariam A, Davis MM.
    Infect Control Hosp Epidemiol; 2008 Dec 15; 29(12):1157-63. PubMed ID: 18999945
    [Abstract] [Full Text] [Related]

  • 8. The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.
    Bye WA, Sparrow MP, Connor SJ, Andrews JM, Ellard K, Ng W, Hume G, Antoniades S, Walsh AJ.
    Intern Med J; 2017 Nov 15; 47(11):1263-1269. PubMed ID: 28516725
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF, Parrino J, Fisher CL, Spieler W, Stek JE, Coll KE, Su SC, Xu J, Li X, Schlienger K, Silber JL.
    Vaccine; 2015 Jun 17; 33(27):3129-34. PubMed ID: 25964168
    [Abstract] [Full Text] [Related]

  • 15. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings.
    Viner K, Perella D, Lopez A, Bialek S, Newbern C, Pierre R, Spells N, Watson B.
    J Infect Dis; 2012 May 01; 205(9):1336-41. PubMed ID: 22454467
    [Abstract] [Full Text] [Related]

  • 16. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
    Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK.
    Expert Opin Biol Ther; 2013 Oct 01; 13(10):1467-77. PubMed ID: 23984934
    [Abstract] [Full Text] [Related]

  • 17. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.
    Vaccine; 2010 Jun 07; 28(25):4204-9. PubMed ID: 20416263
    [Abstract] [Full Text] [Related]

  • 18. Varicella-zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives.
    Luyten J, Ogunjimi B, Beutels P.
    Vaccine; 2014 Dec 12; 32(52):7175-8. PubMed ID: 25454883
    [Abstract] [Full Text] [Related]

  • 19. Providers' lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination.
    Aziz M, Kessler H, Huhn G.
    Int J STD AIDS; 2013 Jun 12; 24(6):433-9. PubMed ID: 23970744
    [Abstract] [Full Text] [Related]

  • 20. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
    Bonmarin I, Santa-Olalla P, Lévy-Bruhl D.
    Rev Epidemiol Sante Publique; 2008 Oct 12; 56(5):323-31. PubMed ID: 18951741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.